Glioblastoma Multiforme Treatment Drugs Market

Global Glioblastoma Multiforme Treatment Drugs Market Size, Share And Trend Analysis Report By Treatment (Surgery, Chemotherapy, Radiation Therapy, Others), By Drug Class (Temozolomide, Bevacizumab, Lomustine, Others), By End-Use (Hospitals, Clinics, Ambulatory Surgical Centers), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025273 | Category : Pharmaceuticals | Delivery Format: /

The global glioblastoma multiforme treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are fuelling the market growth include the growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios, which are anticipated to boost the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period. The increasing incidence of brain tumors is expected to drive the growth of the global glioblastoma multiforme treatment market over the forecast period.

The increasing approval for novel therapy and combination therapy is expected to drive the market in the coming years. For instance, in June 2019, the U.S. FDA approved Pfizer’s Zirabev, a biosimilar for Avastin, for the treatment of recurrent glioblastoma, NSCLC, and colorectal cancer, among others. In January 2020, the company launched its product in the U.S.

The global glioblastoma multiforme treatment drugs market analysis includes some of the key market players such as Sanofi S.A., Eli Lilly and Company, AstraZeneca plc., Astellas Pharma Inc., and Johnson & Johnson (Janss en Pharmaceuticals), among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in November 2019, the U.S. FDA accepted Samsung’s BLA application for its SB8 bevacizumab biosimilar candidate, which will increase the potential to launch products in the coming years.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Bausch Health Companies Inc., Nestlé (Galderma), Leo Pharma Inc., Hovione FarmaCiencia SA, and Aclaris Therapeutics, among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Glioblastoma Multiforme Treatment Drugs Market by Segment

By Treatment 

Surgery

Chemotherapy

Radiation Therapy

Others

By Drug Class 

Temozolomide

Bevacizumab

Lomustine

Others

By End-Use 

Hospitals

Clinics

Ambulatory Surgical Centers

Global Glioblastoma Multiforme Treatment Drugs Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World